



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/398,097	
	Filing Date	4/1/2003	
	First Named Inventor	MIWA, M.	
	Group Art Unit	tba	
	Examiner Name	tba	
Total Number of Pages in This Submission	12	Attorney Docket Number	2795 USOP

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input checked="" type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard. Certificate of Express Mailing Submission of CRF of Sequence Listing IBM PC/AT Format Disk Copy of Notification to Comply
Remarks		The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark Chao, Ph.D., JD, Reg. No. 37,293
Signature	
Date	6/30/04

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class <sup>EXPRESS</sup> mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 6/30/04		
Typed or printed name	Gail L. Winokur	
Signature		Date 6/30/04

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail # EV 410710907 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/799,320

Filed: 3/12/2004

1<sup>st</sup> Inventor: SAIKAWA, Akira

For: Sustained-Release Composition, Method of Its  
Production and Use Thereof

Atty. Dkt. No. 2500 US1P

Art Unit: 1615

Examiner: tba

Allowed:

Batch:

Paper No.:

**CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**

**USPS EXPRESS MAIL LABEL. No. EV 410710907 US**

**DATE IN: June 30, 2004**

**Itemized Papers/Items:**


1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Form (1 page X 2)
3. Response to Notice to Comply with Sequence Listing Requirements (1 page), Submission of CRF of Sequence Listing (5 pages), IBM PC/AT format disk containing the CRF of the Sequence Listing, and copy of Notification to Comply (2 pages).

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP SEQUENCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on this date, 6/30/04

Dated: 6/30/04

  
Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/799,320	Art Unit:	tba
Filed:	3/12/2004	Examiner:	tba
1 <sup>st</sup> Inventor:	SAIKAWA, Akira	Allowed:	
For:	Sustained-Release Composition, Method of its Production and Use Thereof	Batch:	
Atty. Dkt. No.	2500 US1P	Paper No.:	

**Response to Notice of Missing Parts**  
**Sequence Listing Requirements**

**MAIL STOP Missing Parts**  
Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

Sir:

In response to the Notice of Missing Parts mailed 6/16/2004.

Applicants respectfully submit a written Sequence Listing for the Specification and a DOS Text CRF Sequence Listing file "2500us1p.ST25.txt" on the enclosed 3.5" IBM PC/AT computer disk. A copy of the notice is enclosed.

The undersigned hereby certifies that the CRF and the written Sequence Listing are the same in content, with only the addition of the present Serial Number and Filing Date information. The Sequence Listing contains no new matter.

Respectfully submitted,


Dated: June 29, 2004

(847)383-3372  
(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

COPY



UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/799,320	03/12/2004	Akira Saikawa	2500 US1P

CONFIRMATION NO. 8190

23115

TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.  
 INTELLECTUAL PROPERTY DEPARTMENT  
 475 HALF DAY ROAD  
 SUITE 500  
 LINCOLNSHIRE, IL 60069



FORMALITIES LETTER



\*OC000000012945768\*

Date Mailed: 06/16/2004

# **NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov**

Replies should be mailed to: Mail Stop Missing Parts  
 Commissioner for Patents

P.O. Box 1450  
Alexandria VA 22313-1450

---

*A copy of this notice **MUST** be returned with the reply.*



---

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE